Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466)

Ute Linz

doi:10.1002/cncr.24950

Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466)

Cancer. 2010 Apr 15;116(8):1844-6. doi: 10.1002/cncr.24950.

Author

Ute Linz¹

Affiliation

¹ Juelich Research Center, Institute of Neurosciences and Biophysics, Juelich, Germany. u.linz@fz-juelich.de

PMID: 20151424
DOI: 10.1002/cncr.24950

Abstract

Recently, un update of the important European Organization for Research and Treatment of Cancer study 26981 was published without correcting deficiencies that already were known and publicized in 2008. In the current commentary, the author specifies those issues to help prevent incorrect conclusions and discusses reasons why the journal that published the update dismissed a letter clarifying those shortcomings.

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use*
Brain Neoplasms* / drug therapy
Brain Neoplasms* / mortality
Brain Neoplasms* / radiotherapy
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Glioblastoma* / drug therapy
Glioblastoma* / mortality
Glioblastoma* / radiotherapy
Humans
Randomized Controlled Trials as Topic
Temozolomide
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Dacarbazine
Temozolomide